HealthEquity (HQY)
(Delayed Data from NSDQ)
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Zacks News
Encompass Health (EHC) JV Opens Atlanta Rehabilitation Hospital
by Zacks Equity Research
The new facility in Georgia marks the 162nd inpatient rehabilitation hospital of Encompass Health (EHC) in the country.
Encompass Health (EHC) Opens Rehabilitation Hospital in Ballwin
by Zacks Equity Research
The 40-bed inpatient rehabilitation hospital is a JV between Encompass Health (EHC) and BJC HealthCare.
Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
HealthEquity (HQY) Closes Conduent's BenefitWallet Acquisition
by Zacks Equity Research
HealthEquity (HQY) completes the acquisition of Conduent's BenefitWallet HSA portfolio. This is likely to further strengthen the HSA business of HealthEquity.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.
Compared to Estimates, HealthEquity (HQY) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for HealthEquity (HQY) give insight into how the company performed in the quarter ended January 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
HealthEquity (HQY) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 12.50% and 1.48%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) strength in HSAs raises optimism about the stock.
Here's Why HealthEquity (HQY) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Analyst Projections for Key Metrics Reveal About HealthEquity (HQY) Q4 Earnings
by Zacks Equity Research
Evaluate the expected performance of HealthEquity (HQY) for the quarter ended January 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Should You Buy HealthEquity (HQY) Ahead of Earnings?
by Zacks Equity Research
HealthEquity (HQY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why HealthEquity (HQY) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why HealthEquity (HQY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Strength Seen in Agiliti (AGTI): Can Its 29.1% Jump Turn into More Strength?
by Zacks Equity Research
Agiliti (AGTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Surgery Partners (SGRY) Beats Q4 Earnings Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 18.92% and 0.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?